drugset / Trial / NCT01302106
Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes
NaSingle-groupOpen-labelTreatment
Summary
This is an interventional, multicenter, open label, phase II study designed to evaluate the safety and efficacy of Clofarabine in combination with low dose Cytarabine in untreated patients with poor risk of Myelodisplastic Syndromes.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped: “For increased induction mortality in older patients due to specific combinations of drugs, other clinical factors such as patient age and comorbidities.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |